JPS643167B2 - - Google Patents
Info
- Publication number
- JPS643167B2 JPS643167B2 JP4987980A JP4987980A JPS643167B2 JP S643167 B2 JPS643167 B2 JP S643167B2 JP 4987980 A JP4987980 A JP 4987980A JP 4987980 A JP4987980 A JP 4987980A JP S643167 B2 JPS643167 B2 JP S643167B2
- Authority
- JP
- Japan
- Prior art keywords
- administered
- acetylcysteine
- naphthalene
- cataract
- lens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 9
- 229960004308 acetylcysteine Drugs 0.000 claims description 9
- 229940124428 anticataract agent Drugs 0.000 claims description 3
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 12
- 210000000695 crystalline len Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 241000283977 Oryctolagus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000000397 acetylating effect Effects 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4987980A JPS56147715A (en) | 1980-04-15 | 1980-04-15 | Anticataractal agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4987980A JPS56147715A (en) | 1980-04-15 | 1980-04-15 | Anticataractal agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56147715A JPS56147715A (en) | 1981-11-16 |
| JPS643167B2 true JPS643167B2 (cs) | 1989-01-19 |
Family
ID=12843324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4987980A Granted JPS56147715A (en) | 1980-04-15 | 1980-04-15 | Anticataractal agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56147715A (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0610132B2 (ja) * | 1985-11-27 | 1994-02-09 | 千寿製薬株式会社 | 糖尿病性白内障治療薬 |
| KR100927802B1 (ko) * | 2007-09-17 | 2009-11-23 | 재단법인서울대학교산학협력재단 | 백내장 예방 또는 치료용 약제학적 조성물 |
| EP4054553A4 (en) * | 2019-11-08 | 2023-11-29 | Retina Foundation of the Southwest | JOINTS AND IMPLANTS FOR THE TREATMENT OF EYE DISEASES |
-
1980
- 1980-04-15 JP JP4987980A patent/JPS56147715A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56147715A (en) | 1981-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2526059B2 (ja) | 抗潰瘍剤 | |
| US4241086A (en) | Method for treating rheumatism | |
| HU198388B (en) | Process for producing pharmaceutical compositions containing amides of carboxylic acids for treating rheumatic and inflammatoric illnesses | |
| JPS643167B2 (cs) | ||
| US4336260A (en) | Method and compositions using 1-aryl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid for treating depression | |
| US4952564A (en) | Antiallergic agent | |
| US3917832A (en) | Compositions comprising d-thyroxine and d-triiodothyronine | |
| JPH04295428A (ja) | 抗アレルギー剤 | |
| US3644643A (en) | Method of reducing intraocular pressure using glycine | |
| US3998964A (en) | α-Amino-β-(N-benzylthiocarbamoylthio) propionic acid and therapeutic compositions | |
| US5266595A (en) | Method for treatment of cystinuria | |
| JPH0152366B2 (cs) | ||
| US3622676A (en) | Smoking suppression | |
| US5534523A (en) | Anti-aids virus composition | |
| US3920824A (en) | Stable ophthalmic formulation | |
| JPH0157092B2 (cs) | ||
| CN108992456B (zh) | 含有香叶木苷硫酸酯衍生物的药物组合物及其应用 | |
| US4870071A (en) | Prophylactic and therapeutic agnet for hepatic disorder | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| JPS643121A (en) | Remedy for endometriosis | |
| US3798322A (en) | 6 or 7-substituted 4 or 8-(amino-1-methyl-butylamino)quinolines as hypolipidemic agents | |
| JPH10316568A (ja) | 医薬組成物 | |
| EP0216072B1 (en) | Use of dibenz[cd,f]indole derivatives in the prevention of alcohol abuse | |
| JPS63267727A (ja) | Ｓ−ラクトイルグルタチオンおよび／またはその塩を有効成分とする医薬 | |
| US3806594A (en) | Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium |